523 related articles for article (PubMed ID: 24532543)
21. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
Ahmed SS; Lessa FC; Coradin H; Sánchez J; Carvalho MDG; Soda E; Peña C; Fernández J; Cedano D; Whitney CG; Feris-Iglesias J
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S228-S236. PubMed ID: 34469563
[TBL] [Abstract][Full Text] [Related]
22. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
van Werkhoven CH; Hollingsworth RC; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Sanders EA; Bonten MJ
Vaccine; 2016 Jun; 34(28):3275-82. PubMed ID: 27171754
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
[TBL] [Abstract][Full Text] [Related]
24. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
25. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
Gönüllü E; Soysal A; Yıldız I; Aydemir G; Tunç T; Karaböcüoğlu M
Hum Vaccin Immunother; 2020 Oct; 16(10):2504-2508. PubMed ID: 32119602
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
27. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
[TBL] [Abstract][Full Text] [Related]
28. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan.
Naito S; Tanaka J; Nagashima K; Chang B; Hishiki H; Takahashi Y; Oikawa J; Nagasawa K; Shimojo N; Ishiwada N
Epidemiol Infect; 2016 Feb; 144(3):494-506. PubMed ID: 26122538
[TBL] [Abstract][Full Text] [Related]
29. Pneumococcal vaccines and the prevention of community-acquired pneumonia.
Esposito S; Principi N
Pulm Pharmacol Ther; 2015 Jun; 32():124-9. PubMed ID: 24607597
[TBL] [Abstract][Full Text] [Related]
30. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay.
Pírez MC; Algorta G; Chamorro F; Romero C; Varela A; Cedres A; Giachetto G; Montano A
Pediatr Infect Dis J; 2014 Jul; 33(7):753-9. PubMed ID: 24492286
[TBL] [Abstract][Full Text] [Related]
31. The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia.
Sanz-Herrero F; Gimeno-Cardona C; Tormo-Palop N; Fernández-Fabrellas E; Briones ML; Cervera-Juan Á; Blanquer-Olivas J
Vaccine; 2016 Apr; 34(15):1847-52. PubMed ID: 26845737
[TBL] [Abstract][Full Text] [Related]
32. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
Forstner C; Kolditz M; Kesselmeier M; Ewig S; Rohde G; Barten-Neiner G; Rupp J; Witzenrath M; Welte T; Pletz MW;
Vaccine; 2020 Jan; 38(5):1129-1136. PubMed ID: 31761500
[TBL] [Abstract][Full Text] [Related]
33. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.
Wagenvoort GHJ; Vlaminckx BJM; van Kessel DA; Geever RCL; de Jong BAW; Grutters JC; Bos WJW; Meek B; Rijkers GT
Vaccine; 2017 Sep; 35(37):4886-4895. PubMed ID: 28802755
[TBL] [Abstract][Full Text] [Related]
34. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal diagnosis and serotypes in childhood community-acquired pneumonia.
Elemraid MA; Sails AD; Thomas MF; Rushton SP; Perry JD; Eltringham GJ; Spencer DA; Eastham KM; Hampton F; Gennery AR; Clark JE;
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):129-32. PubMed ID: 23537785
[TBL] [Abstract][Full Text] [Related]
36. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina.
López EL; Glatstein E; Ezcurra GC; Iacono M; Teplitz E; Garnero AV; Lazzarini DL; Vázquez M; Contrini MM
J Pediatric Infect Dis Soc; 2018 Feb; 7(1):30-35. PubMed ID: 28339727
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
Zhang T; Zhang J; Shao X; Feng S; Xu X; Zheng B; Liu C; Dai Z; Jiang Q; Gessner BD; Chen Q; Zhu J; Luan L; Tian J; Zhao G
Vaccine; 2021 Jul; 39(33):4620-4627. PubMed ID: 34253417
[TBL] [Abstract][Full Text] [Related]
38. Change in Bacterial Causes of Community-Acquired Parapneumonic Effusion and Pleural Empyema in Children 6 Years After 13-Valent Pneumococcal Conjugate Vaccine Implementation.
Madhi F; Levy C; Morin L; Minodier P; Dubos F; Zenkhri F; Dommergues MA; Mezgueldi E; Levieux K; ; Béchet S; Varon E; Cohen R;
J Pediatric Infect Dis Soc; 2019 Nov; 8(5):474-477. PubMed ID: 30407519
[TBL] [Abstract][Full Text] [Related]
39. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
